These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 10606256)

  • 1. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPT-11: an original spectrum of clinical activity.
    Rothenberg ML
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase I inhibitors: review and update.
    Rothenberg ML
    Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials with the topoisomerase I inhibitors.
    Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
    Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Wethington SL; Wright JD; Herzog TJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):819-31. PubMed ID: 18471053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
    Khayat D; Gil-Delgado M; Antoine EC; Nizri D; Bastian G
    Oncology (Williston Park); 2001 Apr; 15(4):415-29; discussion 429-30, 433-4. PubMed ID: 11346931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Standard therapy of CPT-11 for colorectal cancer].
    Saitoh S; Sakata Y
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1345-51. PubMed ID: 11681240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of chemotherapy for advanced colorectal cancer: new opportunities.
    Bleiberg H
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):42-50. PubMed ID: 8633253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Topoisomerase inhibitors developing in Japan].
    Furue H
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Cunningham D
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent advance in chemotherapy for advanced colorectal cancer].
    Aiba K
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.